| # | Title | Journal | Year | Citations |
|---|
| 1 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer | International Journal of Clinical Oncology | 2018 | 1,187 |
| 2 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer | International Journal of Clinical Oncology | 2020 | 1,123 |
| 3 | Mutational landscape and clonal architecture in grade II and III gliomas | Nature Genetics | 2015 | 729 |
| 4 | Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial | Lancet, The | 2021 | 689 |
| 5 | Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan | British Journal of Cancer | 2010 | 620 |
| 6 | CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study | Lancet Oncology, The | 2013 | 555 |
| 7 | Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria | Surgery Today | 2016 | 541 |
| 8 | Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS | Annals of Oncology | 2018 | 432 |
| 9 | Narrow‐band imaging (NBI) magnifying endoscopic classification of colorectal tumors proposed by the Japan NBI Expert Team | Digestive Endoscopy | 2016 | 410 |
| 10 | Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial | Lancet Oncology, The | 2017 | 398 |
| 11 | Real-Time Use of Artificial Intelligence in Identification of Diminutive Polyps During Colonoscopy | Annals of Internal Medicine | 2018 | 391 |
| 12 | Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2016 | 390 |
| 13 | Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007) | Gastric Cancer | 2018 | 346 |
| 14 | Mesorectal Excision With or Without Lateral Lymph Node Dissection for Clinical Stage II/III Lower Rectal Cancer (JCOG0212) | Annals of Surgery | 2017 | 322 |
| 15 | A Systematic Review and Meta-analysis of the Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Gastric Cancer | Annals of Surgical Oncology | 2007 | 321 |
| 16 | Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials | Lancet Oncology, The | 2020 | 303 |
| 17 | Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial | Lancet Oncology, The | 2012 | 300 |
| 18 | Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy | Cancer | 2007 | 298 |
| 19 | Short-term surgical outcomes from a phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer: Japan Clinical Oncology Group Study JCOG0912 | Gastric Cancer | 2017 | 288 |
| 20 | Poor Survival Rate in Patients with Postoperative Intra-Abdominal Infectious Complications Following Curative Gastrectomy for Gastric Cancer | Annals of Surgical Oncology | 2013 | 278 |
| 21 | TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial | Lancet Oncology, The | 2012 | 267 |
| 22 | Three-arm Phase III Trial Comparing Cisplatin Plus 5-FU (CF) Versus Docetaxel, Cisplatin Plus 5-FU (DCF) Versus Radiotherapy with CF (CF-RT) as Preoperative Therapy for Locally Advanced Esophageal Cancer (JCOG1109, NExT Study) | Japanese Journal of Clinical Oncology | 2013 | 257 |
| 23 | Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial | Lancet Respiratory Medicine,the | 2017 | 252 |
| 24 | Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer | Journal of Thoracic and Cardiovascular Surgery | 2014 | 245 |
| 25 | KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue Only | PLoS ONE | 2012 | 243 |
| 26 | Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer | Journal of Clinical Oncology | 2018 | 230 |
| 27 | Outcome of ratio of lymph node metastasis in gastric carcinoma | Annals of Surgical Oncology | 2002 | 229 |
| 28 | Long-term Outcomes After Resection for Submucosal Invasive Colorectal Cancers | Gastroenterology | 2013 | 228 |
| 29 | Prognostic relevance of genetic alterations in diffuse lower-grade gliomas | Neuro-Oncology | 2018 | 225 |
| 30 | Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301) | Lancet Oncology, The | 2012 | 213 |
| 31 | Clinical practice guidelines for the management of biliary tract cancers 2015: the 2nd English edition | Journal of Hepato-Biliary-Pancreatic Sciences | 2015 | 205 |
| 32 | A Scoring System to Stratify Curability after Endoscopic Submucosal Dissection for Early Gastric Cancer: “eCura system” | American Journal of Gastroenterology | 2017 | 198 |
| 33 | Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial | Annals of Oncology | 2019 | 195 |
| 34 | Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system | Cancer Science | 2014 | 194 |
| 35 | Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT) | Clinical Cancer Research | 2019 | 191 |
| 36 | Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G) | Annals of Oncology | 2016 | 189 |
| 37 | Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial | The Lancet Gastroenterology and Hepatology | 2020 | 188 |
| 38 | Phase II study of sunitinib as second-line treatment for advanced gastric cancer | Investigational New Drugs | 2011 | 179 |
| 39 | Iatrogenic perforation associated with therapeutic colonoscopy: A multicenter study in Japan | Journal of Gastroenterology and Hepatology (Australia) | 2007 | 166 |
| 40 | Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer | Journal of Thoracic Oncology | 2012 | 166 |
| 41 | Metabolic activity by 18F–FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC | European Journal of Nuclear Medicine and Molecular Imaging | 2018 | 166 |
| 42 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS | Annals of Oncology | 2019 | 166 |
| 43 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS | Annals of Oncology | 2019 | 165 |
| 44 | A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a): the Japan Clinical Oncology Group study (JCOG0607) | Gastric Cancer | 2018 | 163 |
| 45 | Perfusion weighted magnetic resonance imaging to distinguish the recurrence of metastatic brain tumors from radiation necrosis after stereotactic radiosurgery | Journal of Neuro-Oncology | 2010 | 157 |
| 46 | Endoscopic diagnosis of superficial non‐ampullary duodenal epithelial tumors in Japan: Multicenter case series | Digestive Endoscopy | 2014 | 155 |
| 47 | Size-Based Isolation of Circulating Tumor Cells in Lung Cancer Patients Using a Microcavity Array System | PLoS ONE | 2013 | 151 |
| 48 | Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring | Journal of Infection and Chemotherapy | 2013 | 149 |
| 49 | Anamorelin (ONO‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04) | Cancer | 2018 | 147 |
| 50 | Clinical advantages of robotic gastrectomy for clinical stage I/II gastric cancer: a multi-institutional prospective single-arm study | Gastric Cancer | 2019 | 146 |
